Physician profile
Nuray Gun
NPI 1720073323
$1,163.10
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $363 · 2021: $74.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $233.86 | 2019-2020 | |
| Allergan, INC. | $228.12 | 2020 | |
| Abbvie INC. | $198.48 | 2019-2020 | |
| Janssen Biotech, INC. | $160.12 | 2019-2021 | |
| Qol Medical, LLC | $87.54 | 2019-2020 | |
| Gilead Sciences, INC. | $61.99 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.34 | 2019 | |
| Pfizer INC. | $30.54 | 2019 | |
| Shionogi INC | $23.05 | 2019 | |
| Ucb, INC. | $22.56 | 2019 | |
| Cook Medical LLC | $16.93 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.96 | 2019 | |
| Merck Sharp & Dohme LLC | $13.90 | 2019 | |
| Intercept Pharmaceuticals, INC. | $12.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nuray Gun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.